FORADIL AEROLIZER
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $577.85 | 4 | 0 |
| 2017 | $10,679 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,256 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 26 WEEK RANDOMIZED ACTIVE CONTROLLED SAFETY STUDY OF DOUBLE BLIND FORMOTEROL FUMARATE IN FREE COMBINATION WITH AN INHALED CORTICOSTEROID VERSUS AN INHALED CORTICOSTEROID IN ADOLESCENT AND ADULT PATIENTS WITH PERSISTENT ASTHMA | Novartis Pharmaceuticals Corporation | $11,256 | 0 |
Top Doctors Receiving Payments for FORADIL AEROLIZER
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Tucson, AZ | $11,256 | 10 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $11,256
- Total Doctors 0
- Transactions 10
About FORADIL AEROLIZER
FORADIL AEROLIZER is a drug associated with $11,256 in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $577.85 was paid across 4 transactions to 0 doctors.
The most common payment nature for FORADIL AEROLIZER is "Unspecified" ($11,256, 100.0% of total).
FORADIL AEROLIZER is associated with 1 research study, including "A 26 WEEK RANDOMIZED ACTIVE CONTROLLED SAFETY STUDY OF DOUBLE BLIND FORMOTEROL FUMARATE IN FREE COMBINATION WITH AN INHALED CORTICOSTEROID VERSUS AN INHALED CORTICOSTEROID IN ADOLESCENT AND ADULT PATIENTS WITH PERSISTENT ASTHMA" ($11,256).